Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1681/ASN.2008111144

Indexing Status
Subject indexing assigned by NLM

MeSH
Albuminuria /drug therapy /economics; Amides /therapeutic use; Biphenyl Compounds /therapeutic use; Cost-Benefit Analysis; Diabetes Mellitus, Type 2 /drug therapy /economics; Diabetic Nephropathies /drug therapy; Disease Progression; Fumarates /therapeutic use; Health Care Costs; Humans; Hypertension /drug therapy /economics; Losartan /administration & dosage /therapeutic use; Quality-Adjusted Life Years; Tetrazoles /therapeutic use

AccessionNumber
22009103870

Date bibliographic record published
10/03/2010